source
- AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor dealAbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
- Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater ChinaPfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…